Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma

Histone deacetylase (HDAC) enzymatic activity has been linked to the transcription of DNA in cancers including multiple myeloma (MM). Therefore, HDAC inhibitors used alone and in combination are being actively studied as novel therapies in MM. In the present study, we investigated the preclinical ac...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Santo, Loredana, Hideshima, Teru, Kung, Andrew L., Tseng, Jen-Chieh, Tamang, David, Yang, Min, Jarpe, Matthew, van Duzer, John H., Mazitschek, Ralph, Ogier, Walter C., Cirstea, Diana, Rodig, Scott, Eda, Homare, Scullen, Tyler, Canavese, Miriam, Bradner, James, Anderson, Kenneth C., Jones, Simon S., Raje, Noopur
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2012
Assuntos:
Lymphoid Neoplasia
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3337713/
https://ncbi.nlm.nih.gov/pubmed/22262760
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2011-10-387365
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados